Original article

Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome

Kathuska Paredes a, Francisco Javier Pastor a, Javier Capilla a,*, Deanna A. Sutton c, Emilio Mayayo b, Annette W. Fothergill c, Josep Guarro a

a Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain
b Unitat de Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain
c Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, TX, USA

ABSTRACT

Background: Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs.

Aims: Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection.

Methods: The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0.8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg.

Results: Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values.

Conclusions: Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy.

© 2013 Revista Iberoamericana de Micología. Published by Elsevier España, S.L.U. All rights reserved.

Terapia antifúngica frente a la infección por Candida guilliermondii en ratones, correlación entre los parámetros farmacodinámicos in vitro y la eficacia in vivo

RESUMEN

Antecedentes: Candida guilliermondii es un patógeno emergente, con reducida sensibilidad al fluconazol y a las equinocandinas.

Objetivos: Evaluar la actividad in vitro de la anidulafungina, en comparación con la de la anfotericina B y el fluconazol, frente a C. guilliermondii y su eficacia en un modelo animal de infección diseminada.

Métodos: La sensibilidad in vitro se valoró mediante microdilución en caldo y curvas de mortalidad. La eficacia in vivo se evaluó mediante la determinación de la carga fungica en riñón de ratones immunosuprimidos con infección diseminada por C. guilliermondii tratados con anfotericina B desoxicolato (0.8 mg/kg i.v.), anfotericina B liposomal (10 mg/kg i.v.), fluconazol (50 mg/kg) o anidulafungina (10 mg/kg).

Resultados: La anfotericina B y la anidulafungina mostraron actividad fungicida, mientras que el fluconazol fue fungistático frente a todas las cepas. En el modelo murino, la anfotericina B liposomal redujo para
toddas las cepas la carga fúngica en riñones, mientras que la anfotericina B desoxicolato, la anidulafungina y el flucanazol fueron efectivas solo en aquellos animales infectados con las cepas de menor valor de concentración mínima inhibitoria (CMI).

Conclusiones: La anfotericina B liposomal mostró la mayor actividad y eficacia frente a C. guilliermondii, en contraste con el limitado efecto del flucanazol y de la anidulafungina. Se necesitan estudios que incluyan cepas con un rango más amplio de CMI que permitan determinar la relación entre la actividad in vitro y la eficacia de la anidulafungina.

© 2013 Revista Iberoamericana de Micología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

The fungus Candida guilliermondii is widely distributed in nature, including the human microbiota of the skin and mucosal surfaces.2,3 Although this species shows a reduced virulence in comparison to other Candida species,4 it is currently considered an emerging pathogen, with a major incidence in Latin America.18 C. guilliermondii has been recognized as the etiologic agent of a wide variety of clinical infections, including disseminated ones mainly in immunocompromised patients,22 and nosocomial outbreaks in surgical patients with intravascular devices.13 Currently, the recommended treatment for invasive candidiasis in neutropenic patients includes caspofungin (CFG) or micafungin (MFC) as first-line therapies, liposomal amphotericin B (LAMB) and anidulafungin (AFG) being alternatives, while flucanazol (FLC) is recommended only when susceptibility to this drug is confirmed.23 However, several studies have shown that C. guilliermondii has a decreased susceptibility to FLC8,15,19, and therapeutic failures associated with isolates with high amphotericin B (AMB) minimal inhibitory concentrations (MICs) have been reported.9,12,24 Although nearly 90% of isolates shows echinocandins MICs equal or lower than clinical breakpoints (CBP) of susceptibility (2 µg/ml),17 similar to other species of Candida, such as C. parapsilosis, some isolates of C. guilliermondii show MICs considerably high.8,15 Available data concerning the AFG efficacy in invasive candidiasis are limited and the potential role of that drug in the clinical practice is poorly known.23 In this context, animal studies can play an important role for a better understanding of the in vitro—in vivo correlation.11 Therefore, our main objective was to evaluate the in vitro and in vivo activities of AFG against different isolates of C. guilliermondii, comparing the results with those of AMB and FLC.

Materials and methods

Fungal isolates

Four clinical isolates of C. guilliermondii (UTHSC 11–142, UTHSC 10–499, UTHSC 11–685 and UTHSC 10–3207) were used in the in vitro study and two of them (UTHSC 11–685 and UTHSC 11–142) were selected for the murine model on the basis of their different in vitro susceptibilities. The isolates were identified by sequencing the internal transcribed spacer (ITS) region and the D1–D2 domains of the RNA, comparing the sequences with those of the type strain of this species.

In vitro studies

The in vitro susceptibility of the four strains to AMB, FLC and AFG was evaluated using a reference broth microdilution method.5 Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were included as quality controls.

Time-kill curves were developed for all the strains according to previous studies.5,20 In brief, a stock solution of each antifungal was prepared, AMB (Sigma–Aldrich Co., St. Louis, USA) and AFG (Pfizer Inc., Madrid, Spain) were dissolved in dimethyl sulfoxide and FLC (Pfizer Inc., Madrid, Spain) in distilled water. Further, drug dilutions were prepared in 9 ml of standard RPMI 1640 medium to obtain concentrations of 0.03, 0.12, 0.5, 1, 2, 8 and 32 µg/ml of each drug. The isolates were subcultured at 35 °C for 24 h on potato dextrose agar (PDA) plates. Cultures of C. guilliermondii were suspended in sterile saline and the resulting suspensions were adjusted at 5 × 10^6 colony forming units (CFU)/ml by haemocytometer counts and by serial plating onto PDA to confirm viability. Dilutions and controls (drug-free) were inoculated with 1 ml of the fungal suspensions, resulting in a starting inoculum of 5 × 10^5 CFU/ml, and incubated at 35 °C. An aliquot of 100 µl from each tube was collected at 0, 2, 4, 6, 8, 24, and 48 h after inoculation and diluted in distilled water; 30 µl of them were cultured onto PDA plates and incubated at 35 °C for 48 h for CFU/ml determination. A CFU decrease of ≥99.9% or 3 log₁₀ CFU/ml was considered fungicidal, while a reduction of <99.9% or <3 log₁₀ unit was considered fungistatic. The limit of detection was 50 CFU/ml. All time-kill curve studies were performed in duplicate.

In vivo studies

Male OF–1 mice (Charles River; Criffa SA, Barcelona, Spain) with a mean weight of 30 g were used in the experiment. Mice were housed in standard boxes with free access to food and water. All animal procedures were supervised and approved by the Universitat Rovira i Virgili Animal Welfare and Ethics Committee.

Mice were rendered neutropenic one day prior to infection by an intraperitoneal (i.p.) injection of 200 mg/kg of cyclophosphamide (Genoxal; Laboratorios Funk SA, Barcelona, Spain) plus an intravenous (i.v.) injection of 5-fluorouracil (Fluorouracilo; Ferrer Farma SA, Barcelona, Spain) at 150 mg/kg.10,14 The day of infection, mice were challenged i.v. with 1 × 10^6 CFU/animal of each of the two strains of C. guilliermondii, UTHSC 11–685 and UTHSC 11–142, in 0.2 ml of sterile saline into the lateral tail vein.34

Groups of eight animals were randomly established for each strain and drug. The groups were treated as follows: amphotericin B deoxycholate (AMBd) (Xalabarder Pharmacy, Barcelona, Spain) at doses of 0.8 mg/kg i.v. once a day (QD); liposomal amphotericin B (LAMB) (Gilead Sciences S.A., Madrid, Spain) at 10 mg/kg i.v., QD; FLC (Pfizer Inc., Madrid, Spain) at 25 mg/kg orally (p.o.) by gavage, twice daily (BID); and AFG (Ecalta; Pfizer Ltd., Sandwich, Kent, United Kingdom) at 10 mg/kg of body weight/dose i.p., QD. All treatments began 24 h after challenge, and lasted for 7 days. Controls received no treatment. To prevent bacterial infections, all mice received 5 mg/kg day cefazidime subcutaneously from days 1 to 7 after infection. Mice were checked daily and were euthanized on day 8 post-infection by CO₂ anaoxia. The efficacy of each drug was evaluated by tissue burden reduction and histopathological studies. Kidneys were aseptically removed, and one of them was weighed and homogenized in 2 ml of sterile saline. Serial 10-fold dilutions of the homogenates were plated onto PDA and incubated for 48 h at 35 °C for CFU/g calculation. For the histopathology study the remaining kidney was fixed with 10% buffered formalin, dehydrated, paraffin embedded, and sliced into 2 µm sections.
which were stained with hematoxylin–eosin (H-E) and periodic acid–Schiff (PAS) stain for examination by light microscopy.

Statistics

Colony counts from tissue were analyzed using the Mann–Whitney U-test, using Graph Pad Prism 4.0 for Windows (GraphPad Software, San Diego, CA, USA). When P values were below 0.05 the differences were considered statistically significant.

Results

In vitro studies

MICs of AMB were 0.25–1 μg/ml, 0.06–0.25 μg/ml for AFG and 0.5–1 μg/ml for FLC. Following the cut-offs of susceptibility for AMB, FLC and AFG against C. guilliermondii,10 all isolates were susceptible to the three drugs. Quality control strains susceptibilities were within the accepted ranges.6

The killing kinetics of AMB showed a fast fungicidal activity that increased with drug concentration. At concentrations equivalent to the MIC, that drug showed a fungicidal effect against three of the four isolates tested (Fig. 1). This activity started immediately after inoculation at concentrations over 1 μg/ml, the fungicidal endpoint being reached after 4 h at 32 μg/ml. AFG at concentrations above 0.5 μg/ml showed fungicidal activity starting after 4 h of incubation. The fungicidal endpoint was reached at 12–24 h of incubation at 32 μg/ml (Fig. 2). FLC showed fungistatic activity against all four isolates (Fig. 3).

In vivo studies

LABM at 10 mg/kg was the only drug able to reduce the fungal load in kidneys of mice infected with each of the two strains, being the reduction significantly higher than that of the other therapies (P ≤ 0.04). AMBd and FLC were only able to reduce the tissue burden in mice infected with the strain that showed the lowest MICs for these two drugs, i.e., 0.25 μg/ml for AMB and 0.5 μg/ml for FLC (P ≤ 0.008). In the case of AFG the fungal load reduction was modest and lower than that for AMBd, and it significantly reduced the tissue burden in kidney only with respect to control group for strain UTHSC 11-685 (P = 0.002) (Fig. 4).

The histological study showed focal infiltration of fungal cells in kidneys of untreated animals and in mice treated with AMBd, FLC or AFG. Kidneys of mice treated with LABM showed only a mild fungal invasion. Signs of necrosis, inflammatory response or parenchyma alterations were not observed in controls neither in treated animals (Fig. 5).

Discussion

The in vitro studies did not reveal decreased susceptibility of C. guilliermondii isolates to FLC or AFG. In agreement with previous studies, time–kill curves of AMB showed a concentration-dependent fungicidal activity against all the isolates,4,5,7 and FLC showed a fungistatic effect regardless of the concentration tested.7 It is known that AMBd exhibits a higher efficacy than its lipidic formulation, especially in kidney, when administered both at the same doses.1 However, pharmacokinetic studies showed that after the administration of 0.75 mg/kg of AMBd the Cmax of AMB attained in mice serum was 0.30 μg/ml.25 However, the AMB MIC of one
Fig. 2. Time-killing kinetics assays of AFG against four strains of *C. guilliermondii*. (●) 0.03 μg/ml, (▲) 0.12 μg/ml, (□) 0.5 μg/ml, (○) 1 μg/ml, (△) 2 μg/ml, (▽) 8 μg/ml, (♦) 32 μg/ml, (●) control. Dashed lines represent a CFU decrease of 3 log_{10} units in growth compared with the initial inoculum (fungicidal activity), dotted lines indicate the quantification limit of the test.

Fig. 3. Time-killing kinetics assays of FLC against four strains of *C. guilliermondii*. (●) 0.03 μg/ml, (▲) 0.12 μg/ml, (□) 0.5 μg/ml, (○) 1 μg/ml, (△) 2 μg/ml, (▽) 8 μg/ml, (♦) 32 μg/ml, (●) control. Dashed lines represent a CFU decrease of 3 log_{10} units in growth compared with the initial inoculum (fungicidal activity), dotted lines indicate the quantification limit of the test.
of the two isolates tested is higher than this value; therefore, we used a high dose of LAMB in order to reach higher concentrations. Indeed, the administration of LAMB at 10 mg/kg was effective in reducing the fungal load of both strains. This fact correlated with killing curves, where AMB achieved its fungicidal activity against the two isolates tested in vivo, at concentrations of 1 μg/ml. To our knowledge, this is the first study that tried to establish a relationship between the killing kinetics and the in vivo experimental efficacy of AFG and FLC against clinical isolates of C. guilliermondii. Only a previous study on echinocandins exists, particularly on caspofungin (CFG) in disseminated infection by C. guilliermondii. CFG at 1 mg/kg was effective in reducing the kidney fungal load in mice infected with one strain of C. guilliermondii with a MIC of 8 μg/ml, while time killing revealed that no fungicidal activity was achieved at concentrations of 64 μg/ml. Conversely, our study showed a concentration-dependent activity of AFG, which at 32 μg/ml exerted a fungicidal activity, as previously reported, at 24 h and at 8 μg/ml. Previous studies reported AFG concentrations in serum and kidney of approximately 13 μg/ml after 7 days of treatment at doses of 10 mg/kg. Here, AFG was able to reduce only modestly the fungal burden in kidneys of neutropenic mice infected with one of the two strains tested, which does not seem to be related with the low AFG MICs difference between the two strains tested (1 dilution), suggesting that the response to AFG treatment is strain dependent. Similarly, FLG was also only able to reduce slightly the fungal burden in kidney of mice challenged with one of the two strains in spite of the dose administrated which reach serum concentrations above the MICs, which was also not surprising due to its fungistatic activity.

In conclusion, our study showed the higher activity and efficacy of LAMB against the two strains of C. guilliermondii, in contrast to the poor effect of FLC and AFG. However, further studies with more isolates of C. guilliermondii representing a wider range of AFG MICs should be carried out to assess if any relationship between MIC values and AFG efficacy exists.

Conflict of interest

None to declare.

References


